Cancer-id: Toward identification of cancer by tumor-derived extracellular vesicles in blood: Toward identification of cancer by tumor-derived extracellular vesicles in blood

L. G. Rikkert; P. Beekman; J. Caro; F. A. W. Coumans; A. Enciso-Martinez; G. Jenster; S. le Gac; W. Lee; T. G. van Leeuwen; G. B. Loozen; A. Nanou; R. Nieuwland; H. L. Offerhaus; C. Otto; D. M. Pegtel; M. C. Piontek; E. van der Pol; L. de Rond; W. H. Roos; R. B. M. Schasfoort; M. H. M. Wauben; H. Zuilhof; L. W. M. M. Terstappen

doi:10.3389/fonc.2020.00608

Cancer-id: Toward identification of cancer by tumor-derived extracellular vesicles in blood: Toward identification of cancer by tumor-derived extracellular vesicles in blood

L. G. Rikkert
, P. Beekman
, J. Caro
, F. A. W. Coumans
, A. Enciso-Martinez
, G. Jenster
, S. le Gac
, W. Lee
, T. G. van Leeuwen
, G. B. Loozen
, A. Nanou
, R. Nieuwland
, H. L. Offerhaus
, C. Otto
, D. M. Pegtel
, M. C. Piontek
, E. van der Pol
, L. de Rond
, W. H. Roos
, R. B. M. Schasfoort

M. H. M. Wauben, H. Zuilhof, L. W. M. M. Terstappen^*

^*Corresponding author for this work

University of Twente
University of Amsterdam
Wageningen University & Research
Delft University of Technology
Erasmus University Rotterdam
Vrije Universiteit Amsterdam
University of Groningen
Utrecht University
Tianjin University

Research output: Contribution to journal › Article › Academic › peer-review

22 Downloads (Pure)

Abstract

Extracellular vesicles (EVs) have great potential as biomarkers since their composition and concentration in biofluids are disease state dependent and their cargo can contain disease-related information. Large tumor-derived EVs (tdEVs, >1μm) in blood from cancer patients are associated with poor outcome, and changes in their number can be used to monitor therapy effectiveness. Whereas, small tumor-derived EVs (<1μm) are likely to outnumber their larger counterparts, thereby offering better statistical significance, identification and quantification of small tdEVs are more challenging. In the blood of cancer patients, a subpopulation of EVs originate from tumor cells, but these EVs are outnumbered by non-EV particles and EVs from other origin. In the Dutch NWO Perspectief Cancer-ID program, we developed and evaluated detection and characterization techniques to distinguish EVs from non-EV particles and other EVs. Despite low signal amplitudes, we identified characteristics of these small tdEVs that may enable the enumeration of small tdEVs and extract relevant information. The insights obtained from Cancer-ID can help to explore the full potential of tdEVs in the clinic.

Original language	English
Article number	608
Journal	Frontiers in oncology
Volume	10
DOIs	https://doi.org/10.3389/fonc.2020.00608
Publication status	Published - 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.3389/fonc.2020.00608

Cancer-id-toward-identification-of-cancer-by-tumor-derived-extracellular-vesicles-in-blood.pdfFinal published version, 2.24 MBLicence: CC BY

Cite this

Rikkert, L. G., Beekman, P., Caro, J., Coumans, F. A. W., Enciso-Martinez, A., Jenster, G., le Gac, S., Lee, W., van Leeuwen, T. G., Loozen, G. B., Nanou, A., Nieuwland, R., Offerhaus, H. L., Otto, C., Pegtel, D. M., Piontek, M. C., van der Pol, E., de Rond, L., Roos, W. H., ... Terstappen, L. W. M. M. (2020). Cancer-id: Toward identification of cancer by tumor-derived extracellular vesicles in blood: Toward identification of cancer by tumor-derived extracellular vesicles in blood. Frontiers in oncology, 10, Article 608. https://doi.org/10.3389/fonc.2020.00608

@article{1a3ac627d867470bad8a0d1fae28516d,

title = "Cancer-id: Toward identification of cancer by tumor-derived extracellular vesicles in blood: Toward identification of cancer by tumor-derived extracellular vesicles in blood",

abstract = "Extracellular vesicles (EVs) have great potential as biomarkers since their composition and concentration in biofluids are disease state dependent and their cargo can contain disease-related information. Large tumor-derived EVs (tdEVs, >1μm) in blood from cancer patients are associated with poor outcome, and changes in their number can be used to monitor therapy effectiveness. Whereas, small tumor-derived EVs (<1μm) are likely to outnumber their larger counterparts, thereby offering better statistical significance, identification and quantification of small tdEVs are more challenging. In the blood of cancer patients, a subpopulation of EVs originate from tumor cells, but these EVs are outnumbered by non-EV particles and EVs from other origin. In the Dutch NWO Perspectief Cancer-ID program, we developed and evaluated detection and characterization techniques to distinguish EVs from non-EV particles and other EVs. Despite low signal amplitudes, we identified characteristics of these small tdEVs that may enable the enumeration of small tdEVs and extract relevant information. The insights obtained from Cancer-ID can help to explore the full potential of tdEVs in the clinic.",

author = "Rikkert, \{L. G.\} and P. Beekman and J. Caro and Coumans, \{F. A. W.\} and A. Enciso-Martinez and G. Jenster and \{le Gac\}, S. and W. Lee and \{van Leeuwen\}, \{T. G.\} and Loozen, \{G. B.\} and A. Nanou and R. Nieuwland and Offerhaus, \{H. L.\} and C. Otto and Pegtel, \{D. M.\} and Piontek, \{M. C.\} and \{van der Pol\}, E. and \{de Rond\}, L. and Roos, \{W. H.\} and Schasfoort, \{R. B. M.\} and Wauben, \{M. H. M.\} and H. Zuilhof and Terstappen, \{L. W. M. M.\}",

year = "2020",

doi = "10.3389/fonc.2020.00608",

language = "English",

volume = "10",

journal = "Frontiers in oncology",

issn = "2234-943X",

publisher = "Frontiers Media S.A.",

}

Rikkert, LG, Beekman, P, Caro, J, Coumans, FAW, Enciso-Martinez, A, Jenster, G, le Gac, S, Lee, W, van Leeuwen, TG, Loozen, GB, Nanou, A, Nieuwland, R, Offerhaus, HL, Otto, C, Pegtel, DM, Piontek, MC, van der Pol, E, de Rond, L, Roos, WH, Schasfoort, RBM, Wauben, MHM, Zuilhof, H & Terstappen, LWMM 2020, 'Cancer-id: Toward identification of cancer by tumor-derived extracellular vesicles in blood: Toward identification of cancer by tumor-derived extracellular vesicles in blood', Frontiers in oncology, vol. 10, 608. https://doi.org/10.3389/fonc.2020.00608

TY - JOUR

T1 - Cancer-id: Toward identification of cancer by tumor-derived extracellular vesicles in blood

T2 - Toward identification of cancer by tumor-derived extracellular vesicles in blood

AU - Rikkert, L. G.

AU - Beekman, P.

AU - Caro, J.

AU - Coumans, F. A. W.

AU - Enciso-Martinez, A.

AU - Jenster, G.

AU - le Gac, S.

AU - Lee, W.

AU - van Leeuwen, T. G.

AU - Loozen, G. B.

AU - Nanou, A.

AU - Nieuwland, R.

AU - Offerhaus, H. L.

AU - Otto, C.

AU - Pegtel, D. M.

AU - Piontek, M. C.

AU - van der Pol, E.

AU - de Rond, L.

AU - Roos, W. H.

AU - Schasfoort, R. B. M.

AU - Wauben, M. H. M.

AU - Zuilhof, H.

AU - Terstappen, L. W. M. M.

PY - 2020

Y1 - 2020

N2 - Extracellular vesicles (EVs) have great potential as biomarkers since their composition and concentration in biofluids are disease state dependent and their cargo can contain disease-related information. Large tumor-derived EVs (tdEVs, >1μm) in blood from cancer patients are associated with poor outcome, and changes in their number can be used to monitor therapy effectiveness. Whereas, small tumor-derived EVs (<1μm) are likely to outnumber their larger counterparts, thereby offering better statistical significance, identification and quantification of small tdEVs are more challenging. In the blood of cancer patients, a subpopulation of EVs originate from tumor cells, but these EVs are outnumbered by non-EV particles and EVs from other origin. In the Dutch NWO Perspectief Cancer-ID program, we developed and evaluated detection and characterization techniques to distinguish EVs from non-EV particles and other EVs. Despite low signal amplitudes, we identified characteristics of these small tdEVs that may enable the enumeration of small tdEVs and extract relevant information. The insights obtained from Cancer-ID can help to explore the full potential of tdEVs in the clinic.

AB - Extracellular vesicles (EVs) have great potential as biomarkers since their composition and concentration in biofluids are disease state dependent and their cargo can contain disease-related information. Large tumor-derived EVs (tdEVs, >1μm) in blood from cancer patients are associated with poor outcome, and changes in their number can be used to monitor therapy effectiveness. Whereas, small tumor-derived EVs (<1μm) are likely to outnumber their larger counterparts, thereby offering better statistical significance, identification and quantification of small tdEVs are more challenging. In the blood of cancer patients, a subpopulation of EVs originate from tumor cells, but these EVs are outnumbered by non-EV particles and EVs from other origin. In the Dutch NWO Perspectief Cancer-ID program, we developed and evaluated detection and characterization techniques to distinguish EVs from non-EV particles and other EVs. Despite low signal amplitudes, we identified characteristics of these small tdEVs that may enable the enumeration of small tdEVs and extract relevant information. The insights obtained from Cancer-ID can help to explore the full potential of tdEVs in the clinic.

UR - https://www.scopus.com/pages/publications/85087360476

U2 - 10.3389/fonc.2020.00608

DO - 10.3389/fonc.2020.00608

M3 - Article

C2 - 32582525

SN - 2234-943X

VL - 10

JO - Frontiers in oncology

JF - Frontiers in oncology

M1 - 608

ER -

Cancer-id: Toward identification of cancer by tumor-derived extracellular vesicles in blood: Toward identification of cancer by tumor-derived extracellular vesicles in blood

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this